Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News May 10 2022 | Heart Failure Awareness 365: Basics of Heart Failure Part II - Heart Failure Treatment Best Practices Patient News Heart Failure Awareness 365 Patient Resource Read More May 10 2022 | From Patient to Agent Practice News Journal of Cardiac Failure Patient Story Press Release Read More May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Apr 26 2022 | Registration is Open for the HFSA Annual Scientific Meeting 2022 Read More Pagination First page « First Previous page ‹ Previous … Page 37 Page 38 Page 39 Page 40 Current page 41 Page 42 Page 43 Page 44 Page 45 … Next page Next › Last page Last »
May 10 2022 | Heart Failure Awareness 365: Basics of Heart Failure Part II - Heart Failure Treatment Best Practices Patient News Heart Failure Awareness 365 Patient Resource Read More
May 10 2022 | From Patient to Agent Practice News Journal of Cardiac Failure Patient Story Press Release Read More
May 6 2022 | FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction Industry News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
